in vitro News and Research

RSS

TriLink signs licensing agreement to use CleanAmp dNTPs in Biofortuna's PCR kits

TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with Biofortuna Ltd. (Biofortuna) for use of CleanAmp dNTPs in Biofortuna's freeze dried in vitro diagnostic PCR kits.

15 Sep 2010

Researchers create artificial human ovary to yield infertility treatments for cancer patients

Researchers at Brown University and Women & Infants Hospital have invented the first artificial human ovary, an advance that provides a potentially powerful new means for conducting fertility research and could also yield infertility treatments for cancer patients. The team has already used the lab-grown organ to mature human eggs.

15 Sep 2010

Hormone melatonin improves egg quality in IVF

Poor egg (oocyte) quality is an important cause of female infertility. Low quality eggs may have several problems, for example they may not divide properly, or they may be missing certain chromosomes. Egg quality also declines with age, and certain medical conditions, such as PolyCystic Ovary Syndrome, can lead to poor quality eggs.

15 Sep 2010

Preliminary injunction against CellzDirect, Invitrogen, and Life Technologies for Liverpool patent infringement

Celsis In Vitro, Inc. announced today that the United States District Court for the Northern District of Illinois in Chicago has entered a preliminary injunction against CellzDirect Inc., Invitrogen Corporation, and Life Technologies (the Defendants) due to their infringement of U.S. Patent No. 7,604,929 (the Liverpool™ patent).

13 Sep 2010

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Swimming in indoor chlorinated pools may induce genotoxicity (DNA damage that may lead to cancer) as well as respiratory effects, but the positive health effects of swimming can be maintained by reducing pool levels of the chemicals behind these potential health risks, according to a new study published in a set of three articles online September 12 ahead of print in the peer-reviewed journal Environmental Health Perspectives (EHP).

13 Sep 2010

Catch by Gene enters agreement with C&S for HPV test kit

Catch by Gene has entered into an agreement to supply its reagent solutions to C&S Company Ltd commencing immediately in the initial amount of $300,000.

13 Sep 2010

Numerate awarded new contract by Defense Threat Reduction Agency

Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.

10 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Cellectis acquires assets of Cyto Pulse Sciences

Cellectis, the French genome engineering specialist, has announced today that it has acquired all the assets of Cyto Pulse Sciences Inc., a US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center.

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Synthetic derivative of Retinoic acid can induce cell death

Retinoic acid (RA), a natural derivative of vitamin A, is the basis of a number of treatments against cancer. Nevertheless, it has certain disadvantages, such as the possibility of the appearance of retinoic acid syndrome, present in 25 % of cases and which can lead to death. The development of 4-HPR, a synthetic derivative of RA, has meant a considerable advance due to its greater efficacy compared to its predecessor.

8 Sep 2010

RA synthetic derivative 4-HPR's ability to induce tumour cell death

7 Sep 2010

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostic systems and consumables for use in hospitals and commercial laboratories worldwide and provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the analysis of synovial fluid as a new product application in its Body Fluids Module utilizing its iQ®200 and iRICELL® automated microscopy analyzers.

7 Sep 2010

DSM, PolyTherics enter agreement for HiPEG IFN alpha-2a product development

DSM BioSolutions, DSM's microbial fermentation CMO business unit and PolyTherics Limited an innovator in precision engineering of proteins, today announced that they have entered into an agreement for the process development and manufacture of PolyTherics' lead biobetter product, HiPEG IFN alpha-2a.

7 Sep 2010

Protagen AG announces € 10.0 Million for second round of finance totaling

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis announced today a second round of finance totalling a volume of € 10.0 Million.

7 Sep 2010

Accentus Medical signs licence agreement for Agluna anti-infective technology with Zimmer

Accentus Medical, a leading UK medical technology company that supplies advanced coatings and surface treatments to the medical device industry, announced today that it has signed a Licence and Services Agreement with Zimmer Holdings, Inc., a global market leader in musculoskeletal care. This agreement will enable the use of Accentus Medical's Agluna® anti-infective technology on a potentially broad range of Zimmer products.

3 Sep 2010

NEJM publishes study on Xpert MTB/RIF test for rapid molecular detection of TB and rifampin resistance

Cepheid today announced that its Xpert® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance." The complete study is now available online (http://www.nejm.org) and will appear in the September 9 print edition.

3 Sep 2010

Researchers identify two proteins in cellular response to mechanical stimulation

Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction.

3 Sep 2010

in vitro News and Research

TriLink signs licensing agreement to use CleanAmp dNTPs in Biofortuna's PCR kits

Researchers create artificial human ovary to yield infertility treatments for cancer patients

Hormone melatonin improves egg quality in IVF

Preliminary injunction against CellzDirect, Invitrogen, and Life Technologies for Liverpool patent infringement

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Catch by Gene enters agreement with C&S for HPV test kit

Numerate awarded new contract by Defense Threat Reduction Agency

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Cellectis acquires assets of Cyto Pulse Sciences

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Zyngenia completes $15M Series A financing extension from NEA

Synthetic derivative of Retinoic acid can induce cell death

RA synthetic derivative 4-HPR's ability to induce tumour cell death

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

DSM, PolyTherics enter agreement for HiPEG IFN alpha-2a product development

Protagen AG announces € 10.0 Million for second round of finance totaling

Accentus Medical signs licence agreement for Agluna anti-infective technology with Zimmer

NEJM publishes study on Xpert MTB/RIF test for rapid molecular detection of TB and rifampin resistance

Researchers identify two proteins in cellular response to mechanical stimulation

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News